The Novo Nordisk Foundation, the philanthropic arm of the Danish pharmaceutical giant, announced Dec. 18 that it has committed $260 million toward the development and improvement of respiratory virus vaccines. The research will be done by the Novo Nordisk Foundation Center for Vaccines and Immunity in partnership with experts at the University of Copenhagen in Denmark.

丹麦制药巨头的慈善机构诺和诺德基金会于12月18日宣布，它已承诺2.6亿美元用于开发和改进呼吸道病毒疫苗。这项研究将由诺和诺德基金会疫苗和免疫中心与丹麦哥本哈根大学的专家合作完成。

The initial focus will be to make improvements to current vaccines for tuberculosis, influenza and Group A Streptococcus. While vaccines do exist for flu and TB, the goal is to make improvements to them with new research, perhaps leading to longer lasting immunity and protections. Understanding more about how to generate immunity in a human airway could be the key leading to longer lasting and 'a potentially revolutionary means to block infection and prevent airborne diseases spreading between humans,' according to the release.Finding a way to bolster immunity in the airway could not only prevent millions of deaths attributed to respiratory viruses annually, but also lessen antimicrobial resistance, which has been a growing threat to global healthcare.'Fundamentally, designing vaccines with a focus on generating immunity in the respiratory system is a relatively unexplored area of research with astounding potential,' Peter Lawætz Andersen, senior vice president of infectious diseases at the Novo Nordisk Foundation, stated in the release.

最初的重点将是改进目前针对结核病、流感和A组链球菌的疫苗。虽然流感和结核病疫苗确实存在，但目标是通过新的研究对其进行改进，也许会导致更持久的免疫力和保护。新闻稿称，更多地了解如何在人体气道中产生免疫力，可能是导致更持久和“一种潜在的革命性手段，可以阻止感染并防止空气传播疾病在人类之间传播”的关键。找到一种增强呼吸道免疫力的方法，不仅可以防止每年数百万人死于呼吸道病毒，还可以减少抗菌素耐药性，这对全球医疗保健构成了越来越大的威胁。”诺和诺德基金会（Novo Nordisk Foundation）传染病高级副总裁彼得·罗茨·安德森（PeterLawætz Andersen）在新闻稿中表示，从根本上讲，设计疫苗的重点是在呼吸系统产生免疫力，这是一个相对未开发的研究领域，具有惊人的潜力。

'We hope that NIVI’s work can help prepare us for the next pandemic, or even help consign airborne epidemics to history.'In 2024, the company will select a leader to oversee both the research arm, Novo Nordisk Foundation Center for Vaccines and Immunity, and its limited liability arm, the Novo Nordisk Foundation Vaccine Accelerator..

“我们希望NIVI的工作能够帮助我们为下一次大流行做好准备，甚至有助于将空气传播的流行病推向历史。”2024年，该公司将选择一位领导者来监督研究部门诺和诺德基金会疫苗与免疫中心及其有限责任部门诺和诺德基金会疫苗加速器。。